Novelna develops proteomics‑based screening tests that deliver markedly higher accuracy than existing diagnostics, targeting diseases that currently lack effective early detection. By leveraging a cost‑efficient platform for discovery and validation, they accelerate the creation of novel diagnostic pipelines, aiming to reduce the high mortality associated with cancers lacking screening options. Their approach combines advanced protein analysis with streamlined development to bring affordable, high‑performance tests to market.
Funding
Funding not disclosed
Founders
Product
Problem
Current screening tests for many cancers and other diseases are either unavailable, lack sufficient accuracy, or are too costly to develop, leading to missed early detection opportunities and poorer patient outcomes.
Solution
Novelna leverages an AI‑enabled proteomics platform to discover and validate protein biomarkers rapidly and at reduced cost. By integrating high‑precision protein measurement with advanced machine‑learning algorithms, the company creates blood‑based and urine‑based diagnostic panels that achieve markedly higher accuracy than existing tests. Their proprietary, multi‑disease discovery pipeline accelerates the transition from biomarker identification to clinically validated assays, enabling early detection across a broad range of indications. The resulting tests are designed to be scalable, affordable, and deployable in standard clinical laboratories, expanding access to reliable early‑disease screening.
Target Audience
Primary customers are clinical laboratories, healthcare providers, and diagnostic manufacturers seeking highly accurate, cost‑effective early detection tests for cancer and other diseases.
Features
- AI‑driven analysis of high‑throughput proteomic data to pinpoint disease‑specific biomarkers
- Proprietary pipeline that streamlines biomarker discovery, panel design, and independent cohort validation
- Blood‑based and urine‑based diagnostic panels optimized for early detection of asymptomatic cancer patients
- Scalable platform architecture that reduces discovery and validation costs compared to traditional methods
- Multi‑disease approach allowing rapid adaptation of the technology to new indications beyond oncology